Canadian Ticagrelor Survey

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01757483
Recruitment Status : Completed
First Posted : December 31, 2012
Last Update Posted : December 9, 2015
Information provided by (Responsible Party):

Brief Summary:
This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Condition or disease
Acute Coronary Syndrome

Detailed Description:
Effectiveness of risk minimisation interventions for ticagrelor in Canada

Study Type : Observational
Actual Enrollment : 244 participants
Time Perspective: Cross-Sectional
Official Title: Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada
Study Start Date : November 2012
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Ticagrelor
U.S. FDA Resources


Primary Outcome Measures :
  1. KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue) [ Time Frame: 2 months ]

Secondary Outcome Measures :
  1. KAU Questionnaire: Practice characteristics [ Time Frame: 2 months ]
  2. KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns [ Time Frame: 2 months ]
  3. KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns. [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All physicians who have prescribed at least one dose of ticargrelor and complete the Knowledge and understanding survey

Inclusion Criteria:

- N/A (All prescribers will be contacted for participation)

Exclusion Criteria:

- Participation in a previous wave of the survey.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01757483

Canada, Quebec
Research Site
Montreal, Quebec, Canada
Sponsors and Collaborators
Principal Investigator: Yola Moride, PhD Université de Montréal

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT01757483     History of Changes
Other Study ID Numbers: D5130L00009
First Posted: December 31, 2012    Key Record Dates
Last Update Posted: December 9, 2015
Last Verified: December 2015

Additional relevant MeSH terms:
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs